Lung cancer immunotherapy adjuvant and neoadjuvant indications
Lung cancer immunotherapy adjuvant and neoadjuvant indications
Using combined oral contraceptives may decrease risk of Ovarian, Endometrial and Colorectal cancer
War in Ukraine: Global cancer aid to support refugees
ASCO and WHO to collaborate on quality indicators for cancer facilities
Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is effective but with significant toxicity
Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients
EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM
Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma
Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy in frontline chronic lymphocytic leukaemia
Quizartinib advances overall survival in acute myeloid leukaemia patients
Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients
The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma